(AOF) – Solvay is considering the possibility of separating into two independent listed entities. A first “EssentialCo” entity would include mono-technology activities such as Soda Ash, Peroxides, Silica and Coatis, which are currently grouped in the Chemicals segment, as well as the Special Chem activity. Together, these activities achieved net sales of around €4.1 billion in 2021.
The second entity “SpecialtyCo” would include activities currently grouped in the Materials segment, including in particular the high growth and high margin polymers of Specialty Polymers, the very successful business of Composite Materials, as well as most of the activities of the Solutions segment, including Novecare, Technology Solutions, Aroma Performance as well as Oil & Gas. These activities generated net sales of approximately €6.0 billion in 2021.
Once completed, the separation would create two leaders in their respective sectors, who would benefit from the strategic and financial flexibility necessary to develop their own business models, their markets and their priorities vis-à-vis their stakeholders, said insured Solvay.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.